WINTON GROUP Ltd Takes $4.56 Million Position in ANI Pharmaceuticals, Inc. $ANIP

WINTON GROUP Ltd purchased a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 55,058 shares of the specialty pharmaceutical company’s stock, valued at approximately $4,558,000. WINTON GROUP Ltd owned approximately 0.24% of ANI Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the company. Advisors Asset Management Inc. acquired a new position in shares of ANI Pharmaceuticals during the first quarter worth approximately $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in ANI Pharmaceuticals by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock valued at $736,000 after purchasing an additional 470 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in ANI Pharmaceuticals by 0.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock valued at $3,235,000 after purchasing an additional 423 shares in the last quarter. Jane Street Group LLC bought a new stake in ANI Pharmaceuticals during the 1st quarter valued at $2,706,000. Finally, Norges Bank acquired a new position in ANI Pharmaceuticals during the second quarter worth $625,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on ANIP. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Weiss Ratings lowered shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Guggenheim cut their price target on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research note on Monday, August 10th. Finally, Canaccord Genuity Group decreased their price objective on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a report on Monday, August 10th. Five analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $105.57.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $71.46 on Friday. The company has a fifty day moving average price of $77.58 and a 200-day moving average price of $78.25. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of 15.40 and a beta of 0.45. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. ANI Pharmaceuticals, Inc. has a 1 year low of $69.96 and a 1 year high of $99.39.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The company had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. During the same period last year, the firm earned $1.80 earnings per share. The firm’s revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities research analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current fiscal year.

Insider Activity

In other news, CEO Nikhil Lalwani sold 5,400 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $74.30, for a total value of $401,220.00. Following the transaction, the chief executive officer owned 344,489 shares in the company, valued at $25,595,532.70. The trade was a 1.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $77.00, for a total value of $243,474.00. Following the completion of the transaction, the senior vice president directly owned 75,534 shares of the company’s stock, valued at approximately $5,816,118. This represents a 4.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 21,425 shares of company stock worth $1,687,370 in the last quarter. 8.10% of the stock is owned by corporate insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.